Protocol Ledger

NCT06470191 · Phase II/III · RECRUITING

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Interventional Phase II/III clinical trial protocol NCT06470191 sponsored by Shanghai Jiaolian Drug Research and Development Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-30 Enrollment: 216 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06470191
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)216 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06470191
Protocol FieldVerified Registry Value
NCT IdentifierNCT06470191
Consolidated Lead SponsorShanghai Jiaolian Drug Research and Development Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment216 participants (ESTIMATED)
Registered Start Date2024-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI